Evidence map›Paper›PMID 32434563›Full record

ArticleEnvironmental health : a global access science source2020

Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort.

Francesca Romana Mancini, German Cano-Sancho, Oceane Mohamed, Iris Cervenka, Hanane Omichessan, Philippe Marchand, Marie-Christine Boutron-Ruault, Patrick Arveux, Gianluca Severi, Jean-Philippe Antignac and 1 more

Open access · goldAbstract read
In one paragraph

Article in Environmental health : a global access science source, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Francesca Romana ManciniCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France. Francesca.mancini@gustaveroussy.fr.ORCID 0000-0003-2297-3869
German Cano-SanchoLABERCA, Oniris, INRAE, Nantes, France.
Oceane MohamedCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Iris CervenkaCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Hanane OmichessanCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Philippe MarchandLABERCA, Oniris, INRAE, Nantes, France.
Marie-Christine Boutron-RuaultCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Patrick ArveuxCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Gianluca SeveriCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Jean-Philippe AntignacLABERCA, Oniris, INRAE, Nantes, France.
Marina KvaskoffCESP, Faculté de médecine, Université Paris-Saclay, UVSQ, INSERM, Villejuif, France.
Inserm · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FR

Funding

French League against Cancer .French National Alliance for Life and Health Sciences C17014LS from the Cancer ITMOInserm .Institut Gustave-Roussy .Institut National Du Cancer C17014LS from the Cancer ITMOMutuelle Générale de l'Education Nationale .
6 · The paper itself

Abstract

backgroundBrominated flame retardants (BFRs) are lipophilic substances with endocrine-disrupting properties. To date, only few investigations, mainly retrospective case-control studies, have explored the link between internal levels of BFRs and the risk of breast cancer, leading to conflicting results. We investigated the associations between plasma concentrations of two main groups of BFRs, PBDEs (pentabromodiphenyl ethers) and PBBs (polybrominated biphenyls), and the risk of breast cancer in a nested case-control study.

methodsA total of 197 incident breast cancer cases and 197 controls with a blood sample collected in 1994-1999 were included. Plasma levels of PBDE congeners (BDE-28, BDE-47, BDE-99, BDE-100, BDE153, BDE-154) and of PBB-153 were measured by gas chromatography coupled to high-resolution mass spectrometry. Conditional logistic regression models, adjusted for potential confounders, were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).

resultsWomen were aged 56 years on average at blood draw. All cases, except for one, were diagnosed after menopause, with an average age at diagnosis of 68 years. Overall, we found no evidence of an association between plasma levels of PBDEs and PBB-153 and postmenopausal breast cancer risk (log-concentrations of BFRs yielding non-statistically significant ORs of 0.87 to 1.07). The analysis showed a non-linear inverse association for BDE-100 and BDE-153 and postmenopausal breast cancer risk; nevertheless, these findings were statistically significant only when the exposure was modeled as ng/L plasma (third vs. first quintile: OR = 0.42, 95%CI = 0.19-0.93 and OR = 0.42, 95%CI = 0.18-0.98, respectively) and not when modeled as ng/gr of lipids (OR = 0.58, 95%CI = 0.27-1.25 and OR = 0.53, 95%CI = 0.25-1.17). These results were unchanged in stratified analyses by tumor hormone receptor expression or body mass index.

conclusionsOur results suggest no clear association between internal levels of PBDEs and PBB-153 and the risk of breast cancer in postmenopausal women. However, these findings need to be carefully interpreted, taking into account limitations due to the limited number of women included in the study, the lack of information concerning genetic susceptibility of cases, and the unavailability of exposure assessment during critical windows of susceptibility for breast cancer. More studies are warranted to further investigate the relationships between PBDE and PBB exposure and breast cancer risk.

Indexed as

PostmenopauseBreast NeoplasmsCase-Control StudiesEndocrine DisruptorsEnvironmental PollutantsFemaleFlame RetardantsFranceHalogenated Diphenyl EthersHumansMiddle AgedPolybrominated BiphenylsRisk FactorsEndocrine DisruptorsEnvironmental PollutantsFlame RetardantsHalogenated Diphenyl EthersPolybrominated BiphenylsBiomonitoringBreast cancerBrominated flame retardants (BFRs)E3N cohortPentabromodiphenyl ethers (PBDEs)Polybrominated biphenyls (PBBs)

Identifiers

PMID32434563
PMCPMC7238573
OpenAlexW3027889053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.